ZL-1310 not checked

Zai Lab (Shanghai) Co., Ltd.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
4 active
4 in total · 2 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Small-cell Lung Cancer, Extensive-Stage Small Cell Lung Cancer, Solid Tumors, SCLC
Main trialPhase 3
“The purpose of this study is to evaluate the efficacy and safety of ZL-1310 compared to Investigator's Choice Therapy in participants with relapsed Small Cell Lung Cancer.”In the company’s words, NCT07218146 on ClinicalTrials.gov

Other drugs for Small-cell Lung Cancer

All 118 drugs for Small-cell Lung Cancer

Coming up4

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials4

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 30 Jun 2028 A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
Phase 3Not yet recruiting 30 Jun 2030 A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer
Phase 1/2Recruiting Aug 2027 A Study of ZL-1310 in Participants With Selected Solid Tumors
Phase 1Recruiting 30 May 2027 A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow ZL-1310

Following is part of Solo: you see every change to ZL-1310 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in